Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Iva Staniczková Zambo"'
Autor:
Peter Múdry, Michal Kýr, Ondřej Rohleder, Michal Mahdal, Iva Staniczková Zambo, Marta Ježová, Tomáš Tomáš, Jaroslav Štěrba
Publikováno v:
Journal of Bone Oncology, Vol 28, Iss , Pp 100362- (2021)
Purpose: Conventional osteosarcoma is an orphan disease. Current treatment approaches include combining a three drug chemotherapy schedule and surgery. The 3- and 5-year event-free survival (EFS) in localized disease is roughly 65 and 60%, respective
Externí odkaz:
https://doaj.org/article/d2c6f7ddce29434c93d6a72a9563cdf9
Autor:
Kamila Říhová, Monika Dúcka, Iva Staniczková Zambo, Ladislava Vymětalová, Martin Šrámek, Filip Trčka, Jan Verner, Stanislav Drápela, Radek Fedr, Tereza Suchánková, Barbora Pavlatovská, Eva Ondroušková, Irena Kubelková, Danica Zapletalová, Štěpán Tuček, Peter Múdry, Dagmar Adámková Krákorová, Lucia Knopfová, Jan Šmarda, Karel Souček, Lubor Borsig, Petr Beneš
The transcription factor c-Myb is an oncoprotein promoting cell proliferation and survival when aberrantly activated/expressed, thus contributing to malignant transformation. Overexpression of c-Myb has been found in leukemias, breast, colon and aden
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::84b04ff593300ff6bdf0cde2b3cfb8ff
https://www.zora.uzh.ch/id/eprint/226453/
https://www.zora.uzh.ch/id/eprint/226453/
Autor:
Iva Staniczková Zambo, Michal Mahdal, Jaroslav Štěrba, Michal Kýr, Peter Múdry, Tomáš Tomáš, Ondřej Rohleder, Marta Ježová
Publikováno v:
Journal of Bone Oncology
Journal of Bone Oncology, Vol 28, Iss, Pp 100362-(2021)
Journal of Bone Oncology, Vol 28, Iss, Pp 100362-(2021)
Highlights • A report on the best treatment results on an osteosarcoma cohort. • There has been a lack of improvement in osteosarcoma treatment for the last four decades. • Mifamurtide is the only new drug against osteosarcoma licensed by the E
Autor:
Danica Zapletalová, Jan Skoda, Markéta Hermanová, Karel Zitterbart, Renata Veselská, Michal Kyr, Iva Staniczková Zambo, Jaroslav Sterba, Peter Múdry
Publikováno v:
Cancer biomarkers : section A of Disease markers. 17(1)
Nestin, CD133 and ABCG2 are recently discussed as putative markers, co-expression of which might determine a cancer stem cell (CSC) phenotype in sarcomas. Our study is focused on immunohistochemical analysis of nestin, CD133 and ABCG2 expression in r
Autor:
Iva Staniczková Zambo, Renata Veselská, Markéta Hermanová, Jakub Neradil, Peter Múdry, Jaroslav Sterba, Tomáš Loja, Aleš Hampl, Karel Zitterbart, Alena Nunukova, Jan Skoda
Publikováno v:
Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine. 37(7)
The three most frequent pediatric sarcomas, i.e., Ewing's sarcoma, osteosarcoma, and rhabdomyosarcoma, were examined in this study: three cell lines derived from three primary tumor samples were analyzed from each of these tumor types. Detailed compa
Autor:
Iva Staniczková Zambo, Karel Vesely, Michal Kyr, Renata Veselská, Peter Múdry, Dagmar Adámková Krákorová, Markéta Hermanová, Jaroslav Sterba, Karel Zitterbart
Publikováno v:
Oncology Reports.
Nestin has been detected in various malignancies and its expression correlates with advanced grade in some neoplasms. The aim of this study was to examine nestin expression in high-grade osteosarcomas and to determine its prognostic value. Using immu
Autor:
Renata Veselská, Markéta Hermanová, Jaroslav Sterba, Tomáš Loja, Karel Zitterbart, Karel Vesely, Iva Staniczková Zambo, Petr Chlapek
Publikováno v:
BMC Cancer
BMC Cancer, Vol 8, Iss 1, p 300 (2008)
BMC Cancer, Vol 8, Iss 1, p 300 (2008)
Background Nestin was originally identified as a class VI intermediate filament protein that is expressed in stem cells and progenitor cells in the mammalian CNS during development. This protein is replaced in the adult organism by other intermediate